| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S12808 R48231 |
Meador (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 | Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) | 3rd trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: Yes extrapolated (cont. endpoint) |
2.58 [0.50;13.27] excluded (control group) |
-/5 -/93 | - | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12809 R48232 |
Meador (Topiramate) (Controls unexposed, disease free), 2021 | Language Score in 2 years old children with the Bayley Scales of Infant and Toddler Development (BSID-III) | 3rd trimester | prospective cohort | unexposed, disease free | Adjustment: Yes extrapolated (cont. endpoint) | 2.49 [0.48;12.82] | -/5 -/87 | - | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7714 R22905 |
Husebye (Topiramate) (Controls exposed to Lamotrigine, sick), 2020 | Language impairment age 8 years (Language 20) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
1.19 [0.11;12.82] C excluded (control group) |
1/4 9/41 | 10 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7703 R22883 |
Husebye (Topiramate) (Controls unexposed, disease free), 2020 | Language impairment age 8 years (Language 20) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: Yes |
1.10 [0.10;10.90] excluded (control group) |
1/4 8,250/42,550 | 8,251 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7708 R22893 |
Husebye (Topiramate) (Controls unexposed, sick), 2020 | Language impairment age 8 years (Language 20) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.10 [0.11;10.87] C | 1/4 35/150 | 36 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7307 R21178 |
Bromley (Topiramate), 2016 | Verbal abilities <85 (Wechsler Preschool and Primary Scale of Intelligence (WPPSI) / Wechsler Intelligence Scale for Children (WISC)) (5-9 years old) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 1.59 [0.33;7.69] C | 3/27 4/55 | 7 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.76 [0.63;4.86] | 43 | 36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Controls unexposed, disease free; 2: Topiramate) (Controls unexposed, sick; 3: Topiramate;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 7714, 7703, 12808